WO2007109564A3 - Particules de cellules de levures en tant que véhicules de délivrance d'antigènes par voie orale - Google Patents

Particules de cellules de levures en tant que véhicules de délivrance d'antigènes par voie orale Download PDF

Info

Publication number
WO2007109564A3
WO2007109564A3 PCT/US2007/064208 US2007064208W WO2007109564A3 WO 2007109564 A3 WO2007109564 A3 WO 2007109564A3 US 2007064208 W US2007064208 W US 2007064208W WO 2007109564 A3 WO2007109564 A3 WO 2007109564A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
yeast cell
yeast
antigens
delivery vehicles
Prior art date
Application number
PCT/US2007/064208
Other languages
English (en)
Other versions
WO2007109564A2 (fr
Inventor
Gary R Ostroff
Donald J Tipper
Original Assignee
Univ Massachusetts
Gary R Ostroff
Donald J Tipper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts, Gary R Ostroff, Donald J Tipper filed Critical Univ Massachusetts
Publication of WO2007109564A2 publication Critical patent/WO2007109564A2/fr
Publication of WO2007109564A3 publication Critical patent/WO2007109564A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des particules de cellules de levures (PCL) comprenant un antigène, destinées à être utilisées par exemple comme véhicule de délivrance de l'antigène par voie orale, mucosale, parentérale ou par inhalation. Une PCL peut être obtenue à partir d'une cellule de levure par un procédé qui enlève au moins une partie du mannane de la couche de paroi cellulaire externe afin d'exposer ainsi au moins une partie du β-1,3-glucane de la paroi cellulaire. L'antigène peut être exprimé sous la forme d'une fusion de la protéine antigénique avec une séquence protéinique d'ossature qui va permettre à l'antigène de s'agréger dans le cytoplasme de la levure. Des exemples d'ossatures comprennent des protéines, par exemple des protéines de la capside virale qui s'assemblent en particules analogues à un virus dans le cytoplasme de la levure ainsi que des protéines ou peptides capables de s'auto-agréger.
PCT/US2007/064208 2006-03-17 2007-03-16 Particules de cellules de levures en tant que véhicules de délivrance d'antigènes par voie orale WO2007109564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78349306P 2006-03-17 2006-03-17
US60/783,493 2006-03-17

Publications (2)

Publication Number Publication Date
WO2007109564A2 WO2007109564A2 (fr) 2007-09-27
WO2007109564A3 true WO2007109564A3 (fr) 2007-12-13

Family

ID=38523201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/064208 WO2007109564A2 (fr) 2006-03-17 2007-03-16 Particules de cellules de levures en tant que véhicules de délivrance d'antigènes par voie orale

Country Status (2)

Country Link
US (1) US20080044438A1 (fr)
WO (1) WO2007109564A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2006032039A2 (fr) * 2004-09-17 2006-03-23 University Of Massachusetts Compositions et leurs utilisations pour deficiences d'enzymes lysosomales
CA2626394A1 (fr) * 2005-10-24 2007-05-03 University Of Massachusetts Particule de paroi cellulaire de levures pour administrer un polynucleotide codant l'osteoprotegerineuses
EP2222283A2 (fr) * 2007-10-29 2010-09-01 University of Massachusetts Proteins de levure membranaire encapsulées de facon multilayer pour l'administration d'acides nucléiques (siadn)
US9006219B2 (en) * 2008-03-12 2015-04-14 Nektar Therapeutics Oligomer-foscarnet conjugates
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
EP2265290B1 (fr) * 2008-04-11 2014-06-04 Nektar Therapeutics Conjugués poly(alkylène oxide)-propanamine substituée par un aryloxy
US8575102B2 (en) * 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
EP2323695B1 (fr) * 2008-08-19 2018-12-05 Nektar Therapeutics Complexes d'acides nucléiques interférents courts
EP2340050A2 (fr) * 2008-09-19 2011-07-06 Nektar Therapeutics Conjugués polymères de peptides de type aod
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
WO2010033222A2 (fr) * 2008-09-19 2010-03-25 Netkar Therapeutics Conjugués polymères de peptides ziconotides
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
US20110206633A1 (en) * 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
WO2010033227A1 (fr) * 2008-09-19 2010-03-25 Nektar Therapeutics Conjugués polymères de peptides thymosines alpha 1
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
EP2334333A1 (fr) * 2008-09-19 2011-06-22 Nektar Therapeutics Conjugués polymères de peptides analogues à v-681
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
US20110171165A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
EP2340047A1 (fr) * 2008-09-19 2011-07-06 Nektar Therapeutics Conjugués de polymère de peptides kiss1
EP2400989B1 (fr) 2009-02-24 2016-08-10 Nektar Therapeutics Conjugués gabapentine-peg
WO2010120386A1 (fr) 2009-04-17 2010-10-21 Nektar Therapeutics Conjugués inhibiteur de protéine tyrosine kinase-oligomère
WO2010120388A1 (fr) 2009-04-17 2010-10-21 Nektar Therapeutics Conjugués inhibiteur de protéine tyrosine kinase-oligomère
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
KR101799113B1 (ko) 2009-05-13 2017-11-17 넥타르 테라퓨틱스 올리고머를 함유하는 치환된 방향족 트리아진 화합물
US20120164710A1 (en) * 2009-07-03 2012-06-28 Yuan Yuan Fan Method of preparation of a biological particulate structure
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
WO2011103559A1 (fr) 2010-02-22 2011-08-25 Nektar Therapeutics Composés diaromatiques substitués modifiés par un oligomère
WO2011127316A1 (fr) * 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
ES2614181T3 (es) 2010-08-14 2017-05-30 University Of Massachusetts Partícula de pared celular de levadura para suministro de nanopartículas direccionadas al receptor
EP2627639B1 (fr) 2010-10-15 2021-12-22 Nektar Therapeutics Aryl-2-oligomère-3-alcoxypropionamides éventuellement substitués en n
WO2012082995A1 (fr) 2010-12-15 2012-06-21 Nektar Therapeutics Composés d'hydantoïne contenant un oligomère
WO2012083153A1 (fr) 2010-12-16 2012-06-21 Nektar Therapeutics Composés comprenant une fraction apremilast et contenant un oligomère
WO2012088422A1 (fr) 2010-12-22 2012-06-28 Nektar Therapeutics Conjugués promédicaments polymères à plusieurs bras de composés à base de taxane
WO2012088445A1 (fr) 2010-12-22 2012-06-28 Nektar Therapeutics Conjugués promédicaments polymères à plusieurs bras de composés à base de cabazitaxel
US20130338216A1 (en) 2010-12-22 2013-12-19 Nektar Therapeutics Deuterated and/or fluorinated taxane derivatives
JP6002149B2 (ja) 2010-12-23 2016-10-05 ネクター セラピューティクス ポリマー−スニチニブコンジュゲート
US10220020B2 (en) 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US9943605B2 (en) 2010-12-23 2018-04-17 Nektar Therapeutics Polymer-semaxanib moiety conjugates
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
CN111850163A (zh) * 2012-08-19 2020-10-30 财团法人卫生研究院 制备用于以体外转译的方法体外测b型肝炎病毒相关的肝癌变的试剂的用途与体外诊断套组
EP2895457B1 (fr) 2012-09-17 2020-05-20 Nektar Therapeutics Composés à base de benzamide contenant un oligomère
WO2015092819A2 (fr) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Dérivés de 6- (2,3-dichlorophényl) -1,2,4-triazin -5-amine
EP3234141A4 (fr) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Composés reversir tm
EP3334455A4 (fr) * 2015-08-11 2019-08-21 Orbis Health Solutions LLC Stratégie de vaccination bactérienne et virale
WO2017143286A1 (fr) * 2016-02-19 2017-08-24 Wilfred Chen Nanoparticules fonctionnalisées pour la précipitation d'affinité améliorée de protéines
US20180228885A1 (en) * 2016-03-04 2018-08-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
WO2018132496A1 (fr) 2017-01-10 2018-07-19 Nektar Therapeutics Conjugués polymères à bras multiples de composés agonistes de tlr et méthodes de traitement immunothérapeutiques associées
WO2019036031A2 (fr) 2017-08-17 2019-02-21 Nektar Therapeutics Méthode immunothérapeutique de traitement de tumeur
WO2019217243A1 (fr) * 2018-05-06 2019-11-14 University Of Kansas Procédés et compositions associés à la vaccination de nouvelle génération
US20210270821A1 (en) * 2018-07-27 2021-09-02 Sekisui Medical Co., Ltd. IMMUNOASSAY METHOD FOR (carbon 1 to carbon 3 bonded)-BETA-D-GLUCAN IN BIOLOGICAL SAMPLE, ASSAY KIT FOR (carbon 1 to carbon 3 bonded)-BETA-D-GLUCAN, AND ALKALI PRETREATMENT SOLUTION FOR BIOLOGICAL SAMPLE FOR USE IN IMMUNOASSAY METHOD FOR (carbon 1 to carbon 3 bonded)-BETA-D-GLUCAN
CZ308357B6 (cs) * 2019-04-04 2020-06-17 Vysoká škola chemicko-technologická v Praze Způsob výroby kompozitu beta-glukanových částic s inkorporovaným, ve vodě špatně rozpustným, léčivem, farmaceutický přípravek a jejich použití
CN114470228B (zh) * 2021-12-08 2023-06-27 深圳先进技术研究院 一种载凝血药酵母免疫微纳生物机器人及其制备和应用
WO2024026383A1 (fr) * 2022-07-29 2024-02-01 University Of Massachusetts Particules de levure pour l'apport de formulations de cannabinoïdes auto-émulsifiantes activées par l'eau

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
WO2004012657A2 (fr) * 2002-08-01 2004-02-12 Immusonic, Inc. Compositions contenant du beta-glucane, procedes pour produire des beta-glucanes et pour produire et utiliser des beta-glucanes et des conjugues de ces derniers comme adjuvants de vaccins
WO2004058157A2 (fr) * 2002-12-16 2004-07-15 Globeimmune, Inc. Vaccins a base de levure pour immunotherapie
EP1491216A1 (fr) * 2002-03-29 2004-12-29 Japan Science and Technology Agency Medicaments comprenant des nanoparticules proteiques creuses et substance therapeutique destinee a etre a transferee dans des cellules avec lesquelles elles se fondent
US20050281781A1 (en) * 2004-06-16 2005-12-22 Ostroff Gary R Drug delivery product and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
AU657168B2 (en) * 1991-09-18 1995-03-02 Amgen, Inc. Hepatitis B vaccine with bile salt adjuvant
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
DE10247014A1 (de) * 2002-10-09 2004-04-22 Erfle, Volker, Prof. Priv.-Doz. Dr. MHC-Multimere
US20040223976A1 (en) * 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine
KR20050115913A (ko) * 2003-03-26 2005-12-08 사이토스 바이오테크놀로지 아게 Ｍｅｌａｎ―ａ 펩티드 유사체-바이러스-양-입자컨쥬게이트
WO2006032039A2 (fr) * 2004-09-17 2006-03-23 University Of Massachusetts Compositions et leurs utilisations pour deficiences d'enzymes lysosomales
CA2598884A1 (fr) * 2005-02-24 2006-10-05 University Of Massachusetts Acides nucleiques d'influenza, polypeptides et leurs utilisations
CA2626394A1 (fr) * 2005-10-24 2007-05-03 University Of Massachusetts Particule de paroi cellulaire de levures pour administrer un polynucleotide codant l'osteoprotegerineuses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
EP1491216A1 (fr) * 2002-03-29 2004-12-29 Japan Science and Technology Agency Medicaments comprenant des nanoparticules proteiques creuses et substance therapeutique destinee a etre a transferee dans des cellules avec lesquelles elles se fondent
WO2004012657A2 (fr) * 2002-08-01 2004-02-12 Immusonic, Inc. Compositions contenant du beta-glucane, procedes pour produire des beta-glucanes et pour produire et utiliser des beta-glucanes et des conjugues de ces derniers comme adjuvants de vaccins
WO2004058157A2 (fr) * 2002-12-16 2004-07-15 Globeimmune, Inc. Vaccins a base de levure pour immunotherapie
US20050281781A1 (en) * 2004-06-16 2005-12-22 Ostroff Gary R Drug delivery product and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BISHT HIMANI ET AL: "Expression and purification of dengue virus type 2 envelope protein as a fusion with hepatitis B surface antigen in Pichia pastoris", PROTEIN EXPRESSION AND PURIFICATION, vol. 23, no. 1, October 2001 (2001-10-01), pages 84 - 96, XP002453785, ISSN: 1046-5928 *
BOUSSET LUC ET AL: "Structural characterization of the fibrillar form of the yeast Saccharomyces cerevisiae prion Ure2p", BIOCHEMISTRY, vol. 43, no. 17, 4 May 2004 (2004-05-04), pages 5022 - 5032, XP002453786, ISSN: 0006-2960 *
KOURNIKAKIS B ET AL: "Anthrax-protective effects of yeast beta 1,3 glucans", MEDGENMED, WEBMD MEDSCAPE HEALTH NETWORK, NEW YORK, NY, US, vol. 5, no. 1, 21 March 2003 (2003-03-21), pages 1 - 13, XP002364513, ISSN: 1531-0132 *
VETVICKA V ET AL: "Pilot Study: Orally-Administered Yeast beta1,3-glucan Prophylactically Protects Against Anthrax Infection and Cancer in Mice", JOURNAL OF THE AMERICAN NUTRACEUTICAL ASSOCIATION, THE ASSOCIATION, BIRMINGHAM, AL, US, vol. 5, no. 2, 2002, pages 16 - 20, XP002364511, ISSN: 1521-4524 *

Also Published As

Publication number Publication date
US20080044438A1 (en) 2008-02-21
WO2007109564A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007109564A3 (fr) Particules de cellules de levures en tant que véhicules de délivrance d'antigènes par voie orale
WO2010022740A3 (fr) Polypeptides d’enveloppe du vih-1 pour un vaccin contre le vih
WO2008005777A3 (fr) Procédés d'amélioration de l'incorporation de protéines dans des particules de type virus (vlp)
FR15C0079I1 (fr)
WO2010010466A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
JP2009509970A5 (fr)
WO2008099189A3 (fr) Virus de l'herpès simplex et procédés de réplication virale
WO2003068163A3 (fr) Optimisation de sequences de genes de pseudo-particules virales chimeriques pour l'expression de cellules d'insectes
WO2011032161A8 (fr) Vaccins dirigés contre les cellules de langerhans
WO2011056899A3 (fr) Particules de type viral (vlp) chimériques à base de gag de polypeptide rsv-f et de lentivirus ou alpharétrovirus
WO2007099446A3 (fr) Vesicules de type virosome comprenant des antigenes derives de gp41
JP2010515717A5 (fr)
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
WO2008115199A3 (fr) Vaccins viraux chimériques
WO2008078198A3 (fr) Cellules et méthodologie pour générer des virus à arn à brin négatif non segmenté
WO2006059141A3 (fr) Systeme d'administration de proteines
EP3199545A3 (fr) Antigènes réactifs à large spectre optimisés par le calcul pour le virus de la grippe h1n1
WO2011153400A3 (fr) Immunisation par voie nasale
WO2008145401A3 (fr) Protéines structurales de parvovirus mutées en tant que vaccins
WO2003048348A3 (fr) Production de virus, d'isolats viraux et de vaccins
WO2008076255A3 (fr) Lymphopoïétine stromale thymique (tslp) canine et utilisations associées
WO2009012487A3 (fr) Pseudo-particules virales du virus chimère de la varicelle et du zona
WO2010070052A3 (fr) Polypeptides immunogènes comprenant un polypeptide d'ossature et un polypeptide l2 ou un fragment de celui-ci
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
WO2008060385A3 (fr) Efficacité vaccinale améliorée par li-key

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07758728

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PUSUANT TO RULE 112(1) EPC DATED 14.01.2009.

122 Ep: pct application non-entry in european phase

Ref document number: 07758728

Country of ref document: EP

Kind code of ref document: A2